Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Tables)

v3.10.0.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Select condensed consolidated balance sheet line items, which reflect the adoption of ASC 606, are as follows (in thousands):
December 31, 2017
As Reported  Impact of Adoption  As Adjusted 
Prepaids and other current assets  $ 4,241  $ 912  $ 5,153 
Other assets  689  202  891 
Total Assets  $ 343,340  $ 1,114  $ 344,454 
Pharma contract liability  $ —  $ 1,406  $ 1,406 
Long-term pharma contract liability  —  283  283 
Deferred income tax liability, net  6,307  381  6,688 
Stockholders' Equity  172,918  (956) 171,962 
Total Liabilities and Stockholders' Equity  $ 343,340  $ 1,114  $ 344,454 

Select condensed consolidated statement of operations line items, which reflect the adoption of ASC 606, are as follows (in thousands):
For the Twelve Months Ended December 31, 2017 
As Reported  Impact of Adoption  As Adjusted 
Net Revenue 
Clinical Services  $ 231,748  $ (18,651) $ 213,097 
Pharma Services  26,863  291  27,154 
Total Revenue  258,611  (18,360) 240,251 
Gross Margin  120,316  (18,360) 101,956 
Total operating expenses  117,992  (18,938) 99,054 
Income from Operations  2,324  578  2,902 
Interest expense  5,540  5,540 
Other expense  265  (253) 12 
Income tax (benefit)   (2,635) 381  (2,254)
Net Loss  $ (846) $ 450  $ (396)


For the Twelve Months Ended December 31, 2016 
As Reported  Impact of Adoption  As Adjusted 
Net Revenue 
Clinical Services  $ 222,015  $ (11,856) $ 210,159 
Pharma Services  22,068  (419) 21,649 
Total Revenue  244,083  (12,275) 231,808 
Gross Margin  110,379  (12,275) 98,104 
Total operating expenses  107,805  (11,856) 95,949 
Income from Operations  2,574  (419) 2,155 
Interest expense  9,998  —  9,998 
Other expense  —  —  — 
Income tax (benefit)   (1,701) —  (1,701)
Net Loss  $ (5,723) $ (419) $ (6,142)